Gossamer Bio
GOSS
110 hedge funds and large institutions have $97.9M invested in Gossamer Bio in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 40 reducing their positions, and 33 closing their positions.
271% more call options, than puts
Call options by funds: $2.09M | Put options by funds: $564K
7% less funds holding
Funds holding: 118 → 110 (-8)
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
28.03% less ownership
Funds ownership: 109.81% → 81.78% (-28%)
30% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 40
52% less capital inflows, than outflows
Capital inflows: $48M | Capital outflows: $100M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Palo Alto Investors
Palo Alto,
California
|
+$6.56M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.35M |
| 3 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$4.52M |
| 4 |
E
Ergoteles
New York
|
+$3.32M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$50.8M |
| 2 |
Weiss Asset Management
Boston,
Massachusetts
|
-$7.91M |
| 3 |
Rafferty Asset Management
New York
|
-$6.01M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5.39M |
| 5 |
Morgan Stanley
New York
|
-$4.58M |
GOSS Hedge Fund Activity: Q1 2023 in Review
110 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q1 2023, worth a combined $97.9M — down 57% from $225M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of GOSS and 25 opened new positions — a net loss of 8 holders — while 40 trimmed existing stakes and 28 added.
The largest buyer was Palo Alto Investors, adding an estimated $6.56M. The largest seller was State Street, cutting an estimated $50.8M.
- 110 institutional investors held Gossamer Bio (GOSS) as of Q1 2023, down from 118 in Q4 2022.
- Funds reported $97.9M of Gossamer Bio stock for Q1 2023, down 57% quarter-over-quarter.
- 25 funds opened new Gossamer Bio positions in Q1 2023 and 33 closed out, a net change of -8 holders.
- The largest Gossamer Bio buyer in Q1 2023 was Palo Alto Investors, an estimated $6.56M added.
- The largest Gossamer Bio seller in Q1 2023 was State Street, an estimated $50.8M sold.
Based on aggregated 13F filings for Q1 2023.